양극성장애에 대한 Valproic Acid와 Olanzapine 치료 중 발생한 호산구증가증과 전신증상을 동반한 약물발진(DRESS) 증후군 1예 = A Case of Drug Rash with Eosinophilia and Systemic Symptoms Associated with Valproic Acid and Olanzapine Treatment in Patient with Bipolar Disorder

다국어 초록 (Multilingual Abstract)

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a potentially life-threatening, medication-induced hypersensitivity reaction with long latency. It is characterized by fever, rash, leukocytosis with eosinophilia, atypical lymphocytosis, and internal organ involvement. The most common causes of DRESS syndrome are sulfonamides and anticonvulsants such as carbamazepine and lamotrigine. However, valproic acid and olanzapine could develop DRESS syndrome. We report a case of DRESS syndrome associated with valproic acid and olanzapine in a 41 years old male patient with bipolar disorder.

참고문헌 (Reference)

1 Kardaun SH, "Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?" 156 : 609-611, 2007

2 김윤환, "Valproic Acid에 의해 발생한 DRESS 증후군 1예" 대한피부과학회 50 (50): 85-88, 2012

3 Roujeau JC, "Treatment of severe drug eruptions" 26 : 718-722, 1999

4 Coope R, "Treatment of epilepsy with sodium diphenyl hydantoinate" 235 : 490-492, 1940

5 Funck-Brentano E, "Therapeutic management of DRESS: a retrospective study of 38 cases" 72 : 246-252, 2015

6 Cacoub P, "The DRESS syndrome: a literature review" 124 : 588-597, 2011

7 Stamp LK, "Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol" 64 : 2529-2536, 2012

8 Roujeau JC, "Severe adverse cutaneous reactions to drugs" 331 : 1272-1285, 1994

9 Elzagallaai AA, "Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review" 32 : 391-408, 2009

10 Chen YC, "Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan" 68 : 459-465, 2013

11 Hung SI, "HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol" 102 : 4134-4139, 2005

12 Genin E, "HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta analysis" 14 : 281-288, 2014

13 "FDA Drug Safety Communication:FDA warns about rare but serious skin reactions with mental health drug olanzapine (Zyprexa, Zyprexa Zydis, Zyprexa Relprevv, and Symbyax)"

14 Bocquet H, "Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS)" 15 : 250-257, 1996

15 Shiohara T, "Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses" 55 : 1-8, 2006

16 Chen YC, "Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases" 146 : 1373-1379, 2010

17 Kardaun SH, "Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study" 169 : 1071-1080, 2013

18 Walsh SA, "Drug reaction with eosinophilia and systemic symptoms (DRESS): a clinical update and review of current thinking" 36 : 6-11, 2011

19 Husain Z, "DRESS syndrome: Part I. clinical perspectives" 68 : 693.e1-693.e14, 2013

20 Descamps V, "Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms" 137 : 301-304, 2001